Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider Eric R. Olson sold 2,500 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $23.59, for a total value of $58,975.00. Following the transaction, the insider now owns 2,500 shares in the company, valued at approximately $58,975. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) traded down 3.96% during mid-day trading on Tuesday, hitting $22.81. The stock had a trading volume of 141,830 shares. The firm’s 50 day moving average price is $18.74 and its 200-day moving average price is $15.00. The company’s market cap is $597.17 million. Syros Pharmaceuticals, Inc. has a one year low of $8.16 and a one year high of $24.35.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Monday, May 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $1.10 million for the quarter. On average, equities research analysts anticipate that Syros Pharmaceuticals, Inc. will post ($2.15) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Eric R. Olson Sells 2,500 Shares of Syros Pharmaceuticals, Inc. (SYRS) Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/eric-r-olson-sells-2500-shares-of-syros-pharmaceuticals-inc-syrs-stock.html.

Large investors have recently added to or reduced their stakes in the stock. Redmile Group LLC boosted its stake in Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock worth $15,177,000 after buying an additional 4,300 shares during the period. Bank of New York Mellon Corp purchased a new stake in Syros Pharmaceuticals during the first quarter worth about $185,000. Rhumbline Advisers purchased a new stake in Syros Pharmaceuticals during the second quarter worth about $198,000. Wells Fargo & Company MN purchased a new stake in Syros Pharmaceuticals during the first quarter worth about $225,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Syros Pharmaceuticals during the second quarter worth about $343,000. Institutional investors own 49.45% of the company’s stock.

SYRS has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and set a $22.00 price objective on shares of Syros Pharmaceuticals in a research note on Tuesday, May 16th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research note on Wednesday, April 12th. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $20.67.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.